Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Afqlir 40 mg/ml Solution for injection in pre-filled syringe {equilateral_black_triangle}

Active Ingredient:
aflibercept
Company:  
Sandoz Limited See contact details
ATC code: 
S01LA05
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Risk Materials Letters to HCPs Audio/Video
{arrow_left}
{arrow_right}
AFQLIR WAMD Patient Guide - Audio Version

Your guide to Afqlir- for the treatment of neovascular (wet) age-related macular degeneration (AMD)

AFQLIR DMO Patient Guide - Audio Version

Your guide to Afqlir - for the treatment of visual impairment due to diabetic macular oedema (DMO)

AFQLIR BRVO Patient Guide - Audio Version

Your guide to Afqlir - for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)

AFQLIR CRVO Patient Guide - Audio Version

Your guide to Afqlir - for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)

AFQLIR CNV Patient Guide - Audio Version

Your guide to Afqlir - for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV)

Sandoz Limited
Company image
Address
Maxis 1, Western Road, Bracknell, RG12 1RF, UK
WWW
http://www.sandoz.uk.com
WWW
https://pvi1j.solutions.iqvia.com
Telephone
+44 (0) 1276 698020
Medical Information Direct Line
+44 (0)1276 698 101
Medical Information e-mail
[email protected]
Adverse event reporting email
[email protected]
Customer Care direct line
+44 (0)1276 698020
E-mail
[email protected]
E-mail
[email protected]